Literature DB >> 35369378

Use of Immune Checkpoint Inhibitors in End Stage Kidney Disease Patients, Single Center Experience and Review of the Literature.

Jamie S Hirsch1,2,3, Rimda Wanchoo1, Jia H Ng1, Yuriy Khanin1, Kenar D Jhaveri1.   

Abstract

Entities:  

Keywords:  checkpoint inhibitors; dialysis; immunotherapy; nivolumab; onconephrology; pembrolizumab

Mesh：

Substances：

Year:  2020        PMID： 35369378      PMCID： PMC8809292          DOI： 10.34067/KID.0000422020

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  22 in total

1.  Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment.

Authors:  Tadashi Tabei; Ichiro Natsume; Kazuki Kobayashi
Journal:  Int J Urol       Date:  2017-07-21       Impact factor: 3.369

2.  Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.

Authors:  L Spain; R Higgins; K Gopalakrishnan; S Turajlic; M Gore; J Larkin
Journal:  Ann Oncol       Date:  2016-03-06       Impact factor: 32.976

3.  Donor-Derived Metastatic Melanoma and Checkpoint Inhibition.

Authors:  S M Boyle; N Ali; A J Olszanski; D J Park; G Xiao; S Guy; A M Doyle
Journal:  Transplant Proc       Date:  2017-09       Impact factor: 1.066

Review 4.  Toxicities of Immunotherapy for the Practitioner.

Authors:  Jeffrey S Weber; James C Yang; Michael B Atkins; Mary L Disis
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

5.  Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis.

Authors:  Rubens Chang; Keisuke Shirai
Journal:  BMJ Case Rep       Date:  2016-09-22

6.  Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression.

Authors:  Shiho Ishizuka; Shinya Sakata; Chieko Yoshida; Akira Takaki; Sho Saeki; Kazuyoshi Nakamura; Kazuhiko Fujii
Journal:  Respir Investig       Date:  2018-05-10

Review 7.  Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review.

Authors:  Hyeon Cheun; Miso Kim; Hajeong Lee; Kook-Hwan Oh; Bhumsuk Keam
Journal:  Invest New Drugs       Date:  2018-10-08       Impact factor: 3.850

8.  Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.

Authors:  Michael Ong; Andrea Marie Ibrahim; Samuel Bourassa-Blanchette; Christina Canil; Todd Fairhead; Greg Knoll
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

9.  Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis.

Authors:  Alessandro Parisi; Alessio Cortellini; Katia Cannita; Melissa Bersanelli; Corrado Ficorella
Journal:  Case Rep Oncol Med       Date:  2019-02-10

10.  Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review.

Authors:  Jawaher Ansari; Muhammad Ali; Ashraf Farrag; Arwa M Ali; Abdulaziz Alhamad
Journal:  Case Reports Immunol       Date:  2018-06-13
View more
  4 in total

1.  Use of Immune Checkpoint Inhibitors in Elderly Patients With Chronic Kidney Disease and Renal Cell Carcinoma Metastasis of the Parotid Gland: Case Report and Review of the Literature.

Authors:  Andreea Parosanu; Cristina Orlov Slavu; Cristina Pirlog; Ioana M Stanciu; Cornelia Nitipir
Journal:  Cureus       Date:  2022-09-06

2.  Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis.

Authors:  Kaylyn R Collette; Zin W Myint; Saurabh V Parasramka; Carleton S Ellis
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

3.  Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.

Authors:  Komal Akhtar; Metlapalli Venkata Sravanthi; Josephine D'Angelo; Abirami Sivapiragasam
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

Review 4.  Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

Authors:  Sheila Bermejo; Mónica Bolufer; Mar Riveiro-Barciela; Maria José Soler
Journal:  Front Med (Lausanne)       Date:  2022-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.